相关实验视频

Updated: Jul 7, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

术后恶心和吐的经皮电针刺激在接受切割的患者:一项随机对照试验

Liang-Dan Tu¹, Peng-Cheng Li¹, Yu Zhao²

¹Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.

Complementary therapies in clinical practice

|December 27, 2023

概括

通过皮肤在P6针点进行电针点刺激 (TEAS) 可能有助于减少骨切割后的吐和疼痛. 这项研究发现,TEAS在接受这种手术的患者中降低了吐发生率和疼痛得分.

科学领域:

神经外科神经外科
麻醉学麻醉学
综合医学是一个整体的医学.

背景情况:

切术后的恶心和吐 (PONV) 是一个常见的并发症.
心周6 (P6;Neiguan) 针点刺激是PONV的公认治疗方法.
评估TEAS作为抗药的辅助药物,以预防头骨切除术后的PONV至关重要.

研究的目的:

评估P6针点的皮肤电针点刺激 (TEAS) 在P6针点的疗效.
为了确定TEAS是否与抗药物结合,可以预防骨切除术后的PONV.
评估TEAS对疼痛评分的影响以及需要补救性抗/止痛治疗的需要.

主要方法:

一个随机的,安慰剂对照试验,涉及120名预定要进行骨切割的患者.
患者被随机分为两个组:TEAS或假 TEAS.
评估的结果包括PONV发病率,疼痛评分,以及0-2,2-6,6-24小时后使用抗/止痛药.

主要成果:

两组之间患者特征没有显著差异.
与假装组相比,TEAS组的吐发生率在骨切除术后2-6小时内显著降低 (14.0%对29.3%).
疼痛评分在TEAS组明显较低,与假装组相比,在切术后6-24小时内.

结论:

通过皮肤在P6针点进行电针点刺激 (TEAS) 显示了在切术后减少吐发生率的潜力.
TEAS也可能有效降低手术后疼痛评分,在接受切割的患者.
进一步的研究可以探索TEAS作为PONV管理的辅助疗法.

关键词:

进行了切除术 (craniotomy).手术后的恶心和吐.通过皮肤进行电动针点刺激.

更多相关视频

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations

Published on: January 7, 2019

$Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain$ 09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...